Drugs / Eleclazine
last change Feb 2017 re-read 2 minutes ago

Eleclazine

also known as GS-6615 · Eleclazina

Small molecule

Developed for
long QT syndrome · ischemic disease · cardiac rhythm disease · hypertrophic cardiomyopathy · long QT syndrome 2 · long QT syndrome 3
Investigated by
Gilead Sciences

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT02365506 Jul 2015 → May 2016 long QT syndrome 2 Gilead Sciences Completed No outcome recorded
Phase 1 NCT02441829 May → Dec 2015 long QT syndrome Gilead Sciences Completed No outcome recorded
Phase 1 NCT02412098 Mar 2015 → Apr 2016 long QT syndrome Gilead Sciences Completed No outcome recorded
Phase 1 NCT02365532 Feb → May 2015 long QT syndrome Gilead Sciences Completed No outcome recorded
Phase 1 NCT01847391 May → Nov 2013 ischemic disease Gilead Sciences Completed No outcome recorded
Phase 1 NCT01849003 May 2013 → Nov 2014 long QT syndrome Gilead Sciences Completed No outcome recorded
Phase 22 trials
Phase 2 NCT02377336 May 2015 → Aug 2016 ischemic disease Gilead Sciences Withdrawn No outcome recorded
Phase 2 NCT02104583 Sep 2014 → Sep 2016 cardiac rhythm disease Gilead Sciences Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02291237 Feb 2015 → Jan 2017 hypertrophic cardiomyopathy Gilead Sciences Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT02300558 Dec 2014 → Dec 2016 long QT syndrome 3 Gilead Sciences Terminated No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2014-05-09 Gilead Sciences Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome gilead.com

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as Eleclazine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291237
5

NCT02441829

NCT02412098

NCT02104583

NCT02300558

NCT02365506

Known as Eleclazina ChEMBL registry synonym — accepted as the source's own label CHEMBL3707392
Known as GS-6615 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02377336
3

NCT01847391

NCT02365532

NCT01849003

Modality Small molecule CHEMBL3707392
Route Oral “administered orally once daily” NCT01847391